ImCheck Receives EUR 20.18 Million from the French Government
ImCheck has successfully secured significant non-dilutive funding to expedite the development of two groundbreaking programs focused on cancer and infectious diseases, aligning with France's ambitious goal of delivering innovative biomedicines.
Funding Goals and Drug Development Initiatives
ImCheck Therapeutics has announced that it has been awarded EUR 20.18 million in non-dilutive funding through the “i-Démo” initiative, part of the France 2030 Plan, which is managed by Bpifrance on behalf of the French government. This strategic funding is designed to propel the advancement of the company's leading drug candidate, ICT01, which is currently in a Phase I/IIa clinical trial targeting various solid tumors and hematologic malignancies. Moreover, the funding will also facilitate the clinical development of ImCheck’s ICT41 candidate aimed at infectious diseases.
Comments from Leadership on the Funding Award
“We are truly honored to receive support from the France 2030 innovation plan. This recognition reflects the progress we have made in clinical settings and highlights the potential of our innovative immunotherapeutic programs. Our unique and versatile approach allows us to tackle solid tumors, hematologic malignancies, and infectious diseases,” stated Pierre d’Epenoux, Chief Executive Officer of ImCheck Therapeutics. “We are eager to share updates on the ICT01 clinical development program and other corporate advancements in the near future.”
Recognition from Bpifrance and ImCheck's Achievements
Rosalie Maurisse, Head of Healthcare - Innovation division at Bpifrance, remarked, “Through France 2030, Bpifrance is committed to supporting French biotech firms that are at the forefront of drug development innovation, driving significant medical breakthroughs. ImCheck’s pipeline programs stand out distinctly, and we congratulate the company on this award and the funding that will accelerate two of its drug candidates, which align perfectly with the healthcare priorities set by the French Government.”
For five consecutive years, ImCheck has been selected for the French Tech 120 program and has recently earned recognition as a laureate of the French Tech 2030 program in 2024. This acknowledgment places the company among the leading startups enhancing France’s global influence while developing innovative therapies. Such honors, coupled with robust support from a diverse group of prominent international life science investors, have enabled ImCheck to advance its extensive pipeline through both preclinical research and clinical development.
About ImCheck Therapeutics
ImCheck Therapeutics is dedicated to designing and developing a new generation of immunotherapeutic antibodies that target butyrophilins, a novel super-family of immunomodulators. Their lead clinical-stage program, ICT01, showcases a mechanism of action that can modulate both innate and adaptive immunity simultaneously. This “first-in-class” therapy has the potential to deliver superior results compared to traditional immune checkpoint inhibitors and may help overcome resistance when used in combination therapies. Additionally, ImCheck's antagonist antibodies are being explored as potential treatments for a range of autoimmune and infectious diseases.
Expertise and Research Support
ImCheck benefits from the guidance of Prof. Daniel Olive, a global leader in the study of ?9?2 T cells and butyrophilins, along with a seasoned management team and strong backing from notable investors across the US and Europe. This expert support is essential for successfully navigating their innovative research and development initiatives.
Overview of the France 2030 Investment Plan
The France 2030 Investment Plan aims to drive transformative advancements across key sectors such as healthcare, energy, automotive, aerospace, and space through technological innovation. It positions France as a leader in future global initiatives. The plan encompasses a total investment of €54 billion, which is intended to assist businesses, universities, and research organizations in effectively transitioning these strategic sectors while addressing ecological challenges and nurturing future leaders in scientific innovation.
Additional Information
For more information regarding this initiative and other developments within the company, please reach out to ImCheck Therapeutics through the available communication channels.
Frequently Asked Questions
What is the purpose of the funding received by ImCheck?
The funding is aimed at advancing ImCheck's drug candidates, ICT01 and ICT41, through clinical trials and development focused on cancer and infectious diseases.
Who announced the funding for ImCheck?
The funding was announced by ImCheck Therapeutics as part of the France 2030 Plan, which is operated by Bpifrance.
What is ICT01?
ICT01 is ImCheck's lead drug candidate, a pathogen-agnostic ?9?2 T cell-activating monoclonal antibody currently in clinical trials.
How does ImCheck's approach differ from traditional therapies?
ImCheck's immunotherapeutic antibodies target butyrophilins, allowing for modulation of both innate and adaptive immunity, which can lead to better outcomes than traditional immune checkpoint inhibitors.
What recognition has ImCheck received recently?
ImCheck has been selected for the French Tech 120 program for five years and was recognized in 2024 as a laureate of the French Tech 2030 program for its innovative contributions.
